Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma

Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma

Bibliographic Details
Main Authors:	Wei, Guoqing, Nwakuche, Uzoma, Cadavid, Gustavo, Ajaz, Asim, Seiter, Karen, Liu, Delong
Format:	Online
Language:	English
Published:	BioMed Central 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506991/

Similar Items

Ipilimumab-Induced Neutropenia in Melanoma
by: Ban-Hoefen, Makiko, et al.
Published: (2016)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
by: Jeter, Joanne M., et al.
Published: (2012)

Pulmonary strongyloidiasis associated CD3+ large granular lymphocytosis
by: Rishi, Muhammad A, et al.
Published: (2011)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
by: Patel, Sapna P, et al.
Published: (2011)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
by: Della Vittoria Scarpati, Giuseppina, et al.
Published: (2014)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
by: Valpione, Sara, et al.
Published: (2015)

Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
by: Cavalcante, Ludimila, et al.
Published: (2015)

Ipilimumab: Melanoma and beyond
by: Patel, Vishal, et al.
Published: (2011)

Use of ipilimumab in the treatment of melanoma
by: Acharya, Utkarsh H, et al.
Published: (2013)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
by: Ascierto, Paolo Antonio, et al.
Published: (2013)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
by: Piérard, Gérald E., et al.
Published: (2012)

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
by: Chmielowski, Bartosz
Published: (2013)

Acute visual loss after ipilimumab treatment for metastatic melanoma
by: Wilson, Melissa A., et al.
Published: (2016)

Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma
by: Krecké, Nathalie, et al.
Published: (2016)

Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
by: Hahn, Laura, et al.
Published: (2016)

Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma
by: Azmat, Umal, et al.
Published: (2016)

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma
by: Postow, Michael, et al.
Published: (2014)

Hypersensitivity to Mosquito Bites Associated with Natural Killer Cell–derived Large Granular Lymphocyte Lymphocytosis: A Case Report in Korea
by: Chung, Joo Seop, et al.
Published: (2003)

Ipilimumab in patients with melanoma and autoimmune disease
by: Kyi, Chrisann, et al.
Published: (2014)

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
by: Amin, Asim, et al.
Published: (2016)

Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma
by: Mohan, Shalini V., et al.
Published: (2016)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
by: Furudate, Sadanori, et al.
Published: (2016)

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
by: Wang, Wenshi, et al.
Published: (2012)

Ipilimumab and radiation therapy for melanoma brain metastases
by: Silk, Ann W, et al.
Published: (2013)

Ipilimumab for advanced melanoma: A pharmacologic perspective
by: Trinh, Van Anh, et al.
Published: (2013)

Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab
by: Kropp, Lauren M., et al.
Published: (2016)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
by: Tsai, Katy K., et al.
Published: (2015)

Emerging options for the treatment of melanoma – focus on ipilimumab
by: Roddie, Claire, et al.
Published: (2014)

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
by: Andrew Hantel, et al.
Published: (2018-07-01)

Adult-onset cyclic neutropenia is a benign neoplasm associated with clonal proliferation of large granular lymphocytes
Published: (1986)

Persistent γδ T large granular lymphocytosis in a patient with refractory pure red cell aplasia, celiac disease, and chronic hepatitis B infection
by: Sreedharanunni, S, et al.
Published: (2016)

Monoclonal B-Cell Lymphocytosis
by: D’Arena, G., et al.
Published: (2014)

Monoclonal B-cell lymphocytosis☆
by: Biasoli, Irene, et al.
Published: (2015)

Ipilimumab
Published: (2012)

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
by: Voskens, Caroline J., et al.
Published: (2013)

Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma
by: Andrews, Stephanie, et al.
Published: (2012)

Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient
by: Addeo, Alfredo, et al.
Published: (2013)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
by: Ascierto, Paolo A, et al.
Published: (2012)

Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
by: Maccalli, Cristina, et al.
Published: (2013)

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis
by: Wiater, Katarzyna, et al.
Published: (2013)